ethyl 2-(6,8-dimethylimidazo[1,2-a]pyrazin-2-yl)acetate | 1446334-80-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡嗪类
• 英文名称: ethyl 2-(6,8-dimethylimidazo[1,2-a]pyrazin-2-yl)acetate
• 英文别名: Ethyl 2-(6,8-dimethylimidazo[1,2-a]pyrazin-2-yl)acetate
• CAS: 1446334-80-0
• 化学式: C₁₂H₁₅N₃O₂
• 分子量: 233.27
• InChiKey: CAIRAFJFVHMULX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  56.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 2-(6,8-dimethylimidazo[1,2-a]pyrazin-2-yl)acetate 、 tert-butyl (S)-4-(5-formyl-6-hydroxypyridin-2-yl)-2-methylpiperazine-1-carboxylate 在 哌啶 、 溶剂黄146 、 三氟乙酸 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 6.0h， 生成 3-(6,8-dimethylimidazo[1,2-a]pyrazin-2-yl)-7-[(3S)-3-methylpiperazin-1-yl]-2H-pyrano[2,3-b]pyridin-2-one
  参考文献：
  名称：

  Specific Correction of Alternative Survival Motor Neuron 2 Splicing by Small Molecules: Discovery of a Potential Novel Medicine To Treat Spinal Muscular Atrophy

  摘要：

  Spinal muscular atrophy (SMA) is the leading genetic cause of infant and toddler mortality, and there is currently no approved therapy available. SMA is caused by mutation or deletion of the survival motor neuron 1 (SMN1) gene. These mutations or deletions result in low levels of functional SMN protein. SMN2, a paralogous gene to SMN1, undergoes alternative splicing and exclusion of exon 7, producing an unstable, truncated SMI\T07 protein. Herein, we report the identification of a pyridopyrimidinone series of small molecules that modify the alternative splicing of SMN2, increasing the production of fulllength SMN2 mRNA. Upon oral administration of our small molecules, the levels of fulllength SMN protein were restored in two mouse models of SMA. In-depth lead optimization in the pyridopyrimidinone series culminated in the selection of compound 3 (RG7800), the first small molecule SMN2 splicing modifier to enter human clinical trials.

  DOI：

  10.1021/acs.jmedchem.6b00459
• 作为产物：
  描述：

  3,5-二甲基吡嗪-2-胺 、 4-氯乙酰乙酸乙酯 在 二氯甲烷 、 Sodium sulfate-III 、 silica gel 、 甲醇 作用下， 以 乙醇 为溶剂， 反应 16.0h， 以yielded ethyl 2-(6,8-dimethylimidazo[1,2-a]pyrazin-2-yl)acetate as a light brown solid (5 g)的产率得到ethyl 2-(6,8-dimethylimidazo[1,2-a]pyrazin-2-yl)acetate
  参考文献：
  名称：

  COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY

  摘要：

  本文提供了用于治疗脊髓肌肉萎缩症的化合物、其组合物及其使用方法。

  公开号：

  US20150166575A1

文献信息

• Compounds for treating spinal muscular atrophy
  申请人：PTC Therapeutics Inc.

  公开号：US09617268B2

  公开（公告）日：2017-04-11

  Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy. In a specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN2 into mRNA that is transcribed from the SMN2 gene. In another specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 into mRNA that is transcribed from the SMN1 gene. In yet another embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 and SMN2 into mRNA that is transcribed from the SMN1 and SMN2 genes, respectively.

  本文提供了用于治疗脊髓性肌萎缩症的化合物、其组合物和使用方法。在一个具体实施例中，本文提供了一种形式的化合物，可用于调节从SMN2基因转录的mRNA中SMN2的外显子7的包含。在另一个具体实施例中，本文提供了一种形式的化合物，可用于调节从SMN1基因转录的mRNA中SMN1的外显子7的包含。在另一个实施例中，本文提供了一种形式的化合物，可用于调节从SMN1和SMN2基因分别转录的mRNA中SMN1和SMN2的外显子7的包含。
• [EN] COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE L'AMYOTROPHIE SPINALE
  申请人：PTC THERAPEUTICS INC

  公开号：WO2013130689A1

  公开（公告）日：2013-09-06

  Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy.

  本文提供了用于治疗脊髓性肌萎缩症的化合物、组合物及其用途。
• COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY
  申请人：PTC Therapeutics Inc.

  公开号：US20150119380A1

  公开（公告）日：2015-04-30

  Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy. In a specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN2 into mRNA that is transcribed from the SMN2 gene. In another specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 into mRNA that is transcribed from the SMN1 gene. In yet another embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 and SMN2 into mRNA that is transcribed from the SMN1 and SMN2 genes, respectively.

  本文提供了用于治疗脊髓性肌萎缩症的化合物、其组合物及与其一起使用的用途。在一个具体实施例中，本文提供了一种可以用来调节SMN2基因转录的mRNA中包含外显子7的形式化合物。在另一个具体实施例中，本文提供了一种可以用来调节SMN1基因转录的mRNA中包含外显子7的形式化合物。在另一个实施例中，本文提供了一种可以用来调节SMN1和SMN2基因转录的mRNA中包含外显子7的形式化合物。
• US9371336B2
  申请人：——

  公开号：US9371336B2

  公开（公告）日：2016-06-21
• US9617268B2
  申请人：——

  公开号：US9617268B2

  公开（公告）日：2017-04-11